Literature DB >> 12237892

Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri.

Anna H Beskow1, Ulf B Gyllensten.   

Abstract

Cervical cancer is strongly associated with infection by oncogenic forms of human papillomavirus (HPV). Although most women are able to clear an HPV infection, some develop persistent infections that may lead to cancer. The determinants of persistent infection are largely unknown. We have previously shown that women developing carcinoma in situ of the cervix uteri have higher titers of HPV 16 long before development of cervical neoplasia, indicating that the immune response to HPV is important in determining the outcome of an infection. The HLA class II alleles DRB1*1501 and DQB1*0602 have previously been associated with an increased risk of HPV infection, and carriers of these alleles also tend to have more long-term infections. Together these results indicate that certain HLA alleles may affect the ability to control the HPV copy number. To evaluate this possibility, we studied the HLA class II DRB1*1501-DQB1*0602 haplotype, as well as the alleles individually, and the HPV 16 titer in 928 women from a retrospective case-control study (441 cases and 487 controls). Carriers of the haplotype DRB1*1501-DQB1*0602 allele have a significantly higher HPV 16 titer compared to noncarriers (t-test with unequal variance, p = 0.017). An association was found between the HLA haplotype carrier frequency and HPV 16 titer (Mantel-Haenszel statistics p = 0.005). To study whether titer is related to the persistency of infection, women were divided into groups with long-term and short-term infection. A strong correlation is seen between long-term infection and high viral load and between short-term infection and low viral load. These results show that host genetic factors, e.g., variation at the HLA class II loci studied, may affect the immune reaction to the virus and thereby indirectly increase the susceptibility to carcinoma in situ of the cervix uteri. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237892     DOI: 10.1002/ijc.90010

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  The correlation between HLA-DRB1 and HLA-DQB1 gene polymorphisms and cytokines in HPV16 infected women with advanced cervical cancer.

Authors:  Yan Liu; Jian Zhang; Zhong-Ming Jia; Ji-Chang Li; Chun-Hua Dong; Yong-Mei Li
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  High risk HPV types in southern Iranian patients with cervical cancer.

Authors:  S Farjadian; E Asadi; M Doroudchi; A Samsami Dehaghani; S Z Tabei; V P Kumar; A Ghaderi
Journal:  Pathol Oncol Res       Date:  2003-07-14       Impact factor: 3.201

3.  High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease.

Authors:  Patti E Gravitt; Melinda Butsch Kovacic; Rolando Herrero; Mark Schiffman; Concepcion Bratti; Allan Hildesheim; Jorge Morales; Mario Alfaro; Mark E Sherman; Sholom Wacholder; Ana-Cecilia Rodriguez; Robert D Burk
Journal:  Int J Cancer       Date:  2007-12-15       Impact factor: 7.396

4.  Performance assessment of eight high-throughput PCR assays for viral load quantitation of oncogenic HPV types.

Authors:  Roberto Flores-Munguia; Erin Siegel; Walter T Klimecki; Anna R Giuliano
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

Review 5.  Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis.

Authors:  Jill Koshiol; Lisa Lindsay; Jeanne M Pimenta; Charles Poole; David Jenkins; Jennifer S Smith
Journal:  Am J Epidemiol       Date:  2008-05-15       Impact factor: 4.897

Review 6.  Theories of schizophrenia: a genetic-inflammatory-vascular synthesis.

Authors:  Daniel R Hanson; Irving I Gottesman
Journal:  BMC Med Genet       Date:  2005-02-11       Impact factor: 2.103

7.  Circulating interleukin-10 levels and human papilloma virus and Epstein-Barr virus-associated cancers: evidence from a Mendelian randomization meta-analysis based on 11,170 subjects.

Authors:  Kai Qu; Qing Pang; Ting Lin; Li Zhang; Mingliang Gu; Wenquan Niu; Chang Liu; Ming Zhang
Journal:  Onco Targets Ther       Date:  2016-03-07       Impact factor: 4.147

8.  Human Papilloma Virus Genotype Distribution in Cervical lesions in Zanjan, Iran

Authors:  Shahrzad Ahmadi; Hossein Goudarzi; Ahmad Jalilvand; Abdolreza Esmaeilzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2017-12-29

9.  Interaction between polymorphisms of the human leukocyte antigen and HPV-16 variants on the risk of invasive cervical cancer.

Authors:  Patricia S de Araujo Souza; Paulo C Maciag; Karina B Ribeiro; Maria Luiza Petzl-Erler; Eduardo L Franco; Luisa L Villa
Journal:  BMC Cancer       Date:  2008-08-22       Impact factor: 4.430

10.  Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum Cytokine Profiles in Cervical Cancer.

Authors:  Larissa Bahls; Roger Yamakawa; Karina Zanão; Daniela Alfieri; Tamires Flauzino; Francieli Delongui; André de Abreu; Raquel Souza; Fabrícia Gimenes; Edna Reiche; Sueli Borelli; Marcia Consolaro
Journal:  Int J Mol Sci       Date:  2017-08-31       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.